VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical, a biomedical technology company developing a bioelectronic therapy for inflammatory diseases, announced today that it has secured $15 million in an extension to its Series C equity financing, bringing the total raised in this round to $43 million. Proceeds from the financing will be used to support the company’s clinical trials to assess safety and efficacy of its bioelectronic therapy in rheumatoid arthritis (RA) and Crohn’s Disease, and to help advance the therapy toward commercialization. This Series C1 round includes the addition of a new, strategic investor, along with participation from SetPoint’s existing syndicate, including three...